Loading company
Cue Biopharma, Inc.
CUE · Nasdaq · ·
Next earnings: November 11, 2026
$25.64-6.6%Sep 29 close
- 1M
- -8.0%
- 6M
- +278.2%
- 1Y
- +18.9%
- 5Y
- -94.3%
CUE · Nasdaq · ·
Next earnings: November 11, 2026
$25.64-6.6%Sep 29 close
Cue Biopharma, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $7.9M | $3M | +166.66% |
| Profit | -$153.1M | -$8.5M | -1,704.61% |
| Profit per share | -$24.14 | -$2.67 | -804.12% |
| Free Cash Flow | -$29M | -$3.4M | -742.65% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“I am pleased with our progress this quarter, advancing our pipeline and strengthening our position for long-term growth,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cue Biopharma (Nasdaq: CUE) is a clinical stage biopharmaceutical company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Cue Biopharma, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Cue Biopharma, Inc. has no earnings call transcript available.